Health Care/Hospital
WuXi AppTec Reports Strong 2020 Annual Results
Revenue Up 28.5% Year-over-Year to RMB16,535 Million Net Profit Attributable to Owners of the Company Up 59.6% Year-over-Year to RMB2,960 Million Diluted EPS Up 56.3% Year-over-Year to RMB1.25 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 48.1% Year-over-Year toRMB3,565 Mil...
2021-03-30 21:10
3978
Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress
SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...
2021-03-30 20:52
4626
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
2021-03-30 20:30
3283
Fosun International Announces 2020 Annual Results: Total Revenue Amounted to RMB136.6 Billion, Gathering Strength to Fuel Growth
2020 Annual Results Summary and Recent Highlights: * Total revenue amounted to RMB136.6 billion. Net profit attributable to owners of the parent wasRMB8.02 billion. Industrial operating profit reached RMB8.15 billion. * Global collaboration has been conducted to develop COVID-19 mRNA va...
2021-03-30 20:03
8393
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
2015
GemVax's highly promising Phase II Alzheimer's disease clinical trial results targeting telomerase published in prestigious Alzheimer's Research & Therapy' journal
SEOUL, South Korea, March 30, 2021 /PRNewswire/ -- GemVax & KAEL Co., Ltd. (Korea: 082270)("GemVax") has announced that a paper on GV1001, a novel Alzheimer's treatment based on telomerase modification, was published onMarch 26 th in the SCI-grade international journal 'Alzheimer's Research & Ther...
2021-03-30 19:21
3907
Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Pivotal study to evaluate the use of novel liquid embolic versus standard of care in treating malignant and benign hypervascular tumors BEDFORD, Mass., March 30, 2021 /PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embol...
2021-03-30 19:02
1207
Frost & Sullivan Reveals How Virtual Care will Impact the Trillion-dollar Global Healthcare Market
SANTA CLARA, Calif., March 30, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that the emergence of theanytime-anywhere care concept with the COVID-19 outbreak has transformed the healthcare sector worldwide, resulting in a surge in demand for digital health applications—especially...
2021-03-30 18:02
1824
HI-NANO: Hisense's new technology inactivates COVID-19 with a rate up to 93.54%
PARIS, March 30, 2021 /PRNewswire/ -- Hisense's HI-NANO technology is certified effective on inducing the novel coronavirus (SARS-CoV-2) with an inhibition rate of 93.54% by Texcell, a global contract research organization. The test was performed at Texcell's laboratory inParis in February 2021. ...
2021-03-30 16:25
8667
Ascletis Announces Investment Escalation in R&D of Cancer Lipid Metabolism and Oral Checkpoint Inhibitors
* Proposed Initiation of a Pivotal Phase II Trial of ASC40 in Combination with Bevacizumab in Chinese Patients with First Relapse of High-grade Astrocytoma * In-house discovered oral PD-L1 inhibitors demonstrated favorable anti-tumor activities in the animal model compared to a marketed anti-...
2021-03-30 08:00
4630
TurtleTree Scientific and JSBiosciences enter into a strategic partnership for the development of cell culture media and contract manufacturing services
SINGAPORE, March 29, 2021 /PRNewswire/ -- JSBiosciences (hereinafter referred to as "JSBio") has just announced a partnership with TurtleTree Scientific (hereinafter referred to as "TTS"). Both parties have signed a letter of intent to collaborate in the development of cell culture media at a com...
2021-03-30 06:00
2104
Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting
Introduction of key technology to accelerate NASH drug discovery by combining 3D disease models and automated AI-based fibrosis quantification PRINCETON, New Jersey, March 30, 2021 /PRNewswire/ -- During the 2021 Society of Toxicology (SOT) Annual Meeting, researchers from Swiss-based InSphero AG...
2021-03-30 05:20
1475
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...
2021-03-30 04:30
5155
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today t...
2021-03-30 04:10
3974
GenScript Biotech Reports Full Year 2020 Financial Results
NANJING, China, Mar. 30, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK) today held its 2020 Annual Results Conference, announcing its business updates and financial performance. The Group earned a USD 390 million revenue, representing a 42.9% YoY growth, and aUSD 260 million ...
2021-03-30 03:19
5772
Amplicore, Inc. Announces Closing of a Successful $4M Seed Funding Round
CINCINNATI, March 30, 2021 /PRNewswire/ -- Amplicore Inc., an early-stage biopharmaceutical company currently developing locally delivered and minimally invasive therapeutic solutions for musculoskeletal diseases, has successfully closed its Series Seed round of funding at$4 million. Investments ...
2021-03-30 02:55
1715
GenScript Biotech Reports Full Year 2020 Financial Results and Business Results
* Reported a revenue of approximately USD 390 million, a 42.9% YoY increase, and a gross profit ofUSD 260 million, achieving YoY growth of 41.9%. * The Group's non-cell therapy business witnessed its fastest growth in five years with a net profit increase of more than 100%; while its cell ther...
2021-03-30 01:35
4412
Fosun Pharma Announces 2020 Annual Results
Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY toRMB2,718 Million SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (...
2021-03-30 00:38
5128
HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....
2021-03-29 22:00
3424
Tigermed Reports 2020 Annual Results With Solid Growth
HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...
2021-03-29 21:21
4667
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55Vietnam's Newest EDM Destination, APLUS SAIGON, Debuts With Star-Studded Soft Opening Weekends Featuring Dombresky and Argy
[Picked up by 273 media titles]
2025-12-30 20:12
ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 271 media titles]
2026-01-01 10:00
CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 263 media titles]
2025-12-29 09:00
